Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2022 Mar 8.
Published in final edited form as: Angew Chem Int Ed Engl. 2021 Feb 1;60(11):5848–5853. doi: 10.1002/anie.202013927

A Systematic Study of Unsaturation in Lipid Nanoparticles Leads to Improved mRNA Transfection In Vivo

Sang M Lee 1, Qiang Cheng 1, Xueliang Yu 1, Shuai Liu 1, Lindsay T Johnson 1, Daniel J Siegwart 1
PMCID: PMC8100975  NIHMSID: NIHMS1657436  PMID: 33305471

Abstract

Lipid nanoparticles (LNPs) represent the leading concept for mRNA delivery. Unsaturated lipids play important roles in nature with potential for mRNA therapeutics but are difficult to access through chemical synthesis. To systematically study the role of unsaturation, modular reactions were utilized to access a library of 91 amino lipids, enabled by the synthesis of unsaturated thiols. An ionizable lipid series (4A3) emerged from in vitro and in vivo screening, where the 4A3 core with a citronellol-based (Cit) periphery emerged as best. We studied the interaction between LNPs and a model endosomal membrane where 4A3-Cit demonstrated superior lipid fusion over saturated lipids, suggesting its unsaturated tail promotes endosomal escape. Furthermore, 4A3-Cit significantly improved mRNA delivery efficacy in vivo via Selective ORgan Targeting (SORT), resulting in 18-fold increased protein expression over parent LNPs. These findings provide insight into how lipid unsaturation promotes mRNA delivery and demonstrate how lipid mixing can enhance efficacy.

Keywords: lipid nanoparticles, mRNA, unsaturated lipids, unsaturated thiols, nanomaterials

Graphical Abstract

graphic file with name nihms-1657436-f0001.jpg

Unsaturated amino lipids were synthesized to study the role of unsaturation in lipid nanoparticle (LNP)-mediated mRNA delivery. A lipid series with a Citronellol tail (4A3-Cit) was identified from a library screen. Employing 4A3-Cit in new Selective ORgan Targeting (SORT) formulation resulted in an 18-fold increase in mRNA expression over saturated LNPs. The findings provide insights to how unsaturation and SORT mixing can promote mRNA delivery.


Beyond functioning as a link between the genetic code of DNA and functional proteins, messenger mRNA (mRNA) has emerged as a versatile tool to produce proteins for therapeutic applications towards cancer, vaccines, and other areas.[1] However, the major challenge of RNA therapeutics remains efficacious delivery. mRNAs are incapable of passing through cellular membranes on their own due to their physiochemical attributes and propensity for degradation. Methods are needed to encapsulate and deliver mRNA inside cells.[2] To address this challenge, lipid nanoparticles (LNPs) represent the leading concept for mRNA delivery. LNPs are composed of multiple lipids, including ionizable amino lipids, which acquire charge during endosomal maturation and allow endosomal escape of RNA into the cytoplasm to enable delivery of the genetic material.[3]

LNPs were initially established as carriers for siRNAs,[4] and have increasingly been explored for delivery of mRNA.[1a, 5] Studies have shown that optimization of LNP carriers for mRNA versus siRNA often require chemical changes to the lipids involved,[4c, 6] as well as the molar relationship of lipids that compose of the formulations.[7] Despite this progress, much remains unknown about structure-activity relationships (SAR) uniting chemistry and efficacy for mRNA delivery. Recently, the field of mRNA therapeutics has started to include unsaturated lipids in LNPs in the form of natural unsaturated fatty acids and its motifs.[8] In nature, unsaturated lipids play a pivotal role in maintaining the stability and fluidity of membranes.[9] The universal importance of unsaturated lipids in natural membranes support a LNP design emulating such a chemical composition. However, there has been no robust study on the optimization of unsaturation for LNPs nor its purpose.

To study the role of unsaturated lipids in LNPs, we focused on an ionizable amino lipid platform created using modular dendrimer growth reactions, where we could systematically introduce unsaturation. Our lipid design consisting of an ionizable amine core, ester-based degradable linker, and alkyl thiol tail periphery[10] was revisited with attention on unsaturation for the periphery. To incorporate unsaturation into the ionizable lipid, we synthesized alkenyl thiols and inserted them as the hydrophobic tail domain, mimicking natural fatty acids. These newly synthesized lipids were formulated into LNPs and compared to their saturated parents. In doing so, we aimed to understand why unsaturation may be important for LNPs and explore the potential applications of unsaturated LNPs.

Modular reactions were utilized to create a chemically diverse library of unsaturated amino lipids. Our synthetic route towards the ionizable lipid involves a nucleophilic amine addition to an ester-based linker, followed by a Michael addition with the thiols. Previous studies solely involved alkyl thiols because unsaturated thiols are not commercially available. Thus, we hypothesized bridging this gap by synthesizing unsaturated thiols from alkenyl alcohols and terpenes found in nature (Scheme 1A). However, initial attempts for the unsaturated thiols proved difficult, resulting in undesired products and low yields.

Scheme 1.

Scheme 1.

Synthesis of unsaturated thiols allowed access to unsaturated lipids. A) Scheme and reaction scope for synthesis of alkenyl thiols using non-allylic and allylic alcohols. B) Scheme and reaction scope for synthesis of ionizable amino lipids using 7 different amine cores with isolated yields reported.

After employing multiple strategies, including the Mitsunobu reaction/reduction and Bunte salt, two methods emerged as optimal based on the alcohol, reaction scale, and yield (Figure S1). For most allylic alcohols, conversion of the alcohol to a bromide and subsequent reaction with NaSH provided thiols at 48% to 91% yield. For non-allylic alcohols and farnesol, tosyl protection of the alcohol and subsequent treatment with NaSH afforded the desired thiols at 19% to 67% yields. Thiol nomenclature was based on the carbon chain length (6/8), position of unsaturation (2–5), configuration (cis/trans), and/or their natural product derivative (Citronellol, Nerol, and Farnesol). In tandem, seven ionizable amines were selected as candidates based on the established optimal pKa of 6.2–6.5 for ionizable lipids.[11] The amines were prepared by reacting with an ester-based linker synthesized as previously described.[10] With the amine cores and thiols in hand, appropriate equivalents of thiols per amine were combined with the modified amines and dimethyl phenyl pyridine as a catalyst to create the desired ionizable, unsaturated lipids (Scheme 1B).

The new lipids were formulated into LNPs using a mix of the synthesized lipid, DOPE, cholesterol, and DMG-PEG2k (15:15:30:3, mol:mol), encapsulating Firefly Luciferase (Luc) mRNA. This ratio was selected based on parameters previously optimized for mRNA delivery.[7c] We evaluated the LNPs in IGROV-I cells (25 ng/well) for cell viability and Luc expression (Figure 1). Assessment of the heat map allowed for determination of SARs with respect to hydrophobic domain and amine core chemical structure. While introducing unsaturation in the tail produced some lipids with improved transfection over parent compounds, this chemical alteration was not a change that automatically and universally improved performance. Rather, the placement and cis/trans configuration of the unsaturation were important in determining whether in vitro mRNA delivery would be improved. For example, 8/2 showed comparable Luc expression to its saturated counterpart (SC8). Among all cores examined in the initial screen, 4A3 was the most efficacious. Therefore, we selected the entirety of the 4A3 series to further evaluate its capabilities and study SAR with respect to the hydrophobic domain.

Figure 1.

Figure 1.

4A3-derived lipids performed best across the lipid series for Luc mRNA delivery to IGROV-I cells. A) Bar graph of the in vitro Luc expression assay shows 4A3–4T as the most potent. B) Heat map of the in vitro Luciferase assay data revealed differences based on position and configuration of the unsaturation.

Next, we evaluated the 4A3 series to assess how the unsaturation variations affected mRNA delivery in vivo, which is the more relevant setting for mRNA therapeutic testing. LNPs were formulated using the same components for in vitro testing in the same molar ratio as described above. C57BL/6 mice were administered with each of the 4A3-based LNP series carrying Luc mRNA via tail-vein injections (Figure 2). Clear differences from the in vitro data appeared. While the six-carbon chain series showed few significant differences amongst each other, the eight-carbon tail series exhibited striking distinctions.

Figure 2.

Figure 2.

Ex vivo imaging shows highest mRNA expression in eight carbon series (0.25 Luc mg/kg). A) Whole body images 6 hours after i.v. administration of LNPs. B) Ex vivo organs imaged 6 hours after administration of LNPs. C) Quantified total radiance of the liver. D) Representation of the 4-component standard LNP in vivo formulation method.

Despite being structurally similar, 4A3-Cit performed better than 4A3-Ne, differing only by a prenyl motif per tail. This disparity is likely due to the increased rigidity based on this structural difference. The comparison of the duo suggests that the “stiffness” of the components and its ability to promote membrane permeability may be an important factor in improving mRNA delivery when tailoring to its unsaturation. With 4A3–8/2, it exhibited lower Luc expression compared to its alkyl partner, suggesting again that the introduction of unsaturation alone is not sufficient to increase efficacy. Efficacy did not significantly correlate with size, PDI, or encapsulation efficiency (Figure S5), suggesting that chemical structure was the major driver of efficacy. Moreover, the introduction of unsaturation did not change the biodistribution of 4A3-SC8 and saturated 4A3-Cit based LNPs (Figure S8). As endosomal escape of LNPs remains a major challenge that correlates with amino lipid chemistry, we postulated that these LNPs may differ based on their ability to escape the endosome.[3]

To gain mechanistic insight into this foray, the following assay was conducted to study how our LNPs interacted with a model endosomal membrane. We employed a fluorescence resonance energy transfer (FRET)-based assay to determine the LNP’s ability to disrupt and fuse with the endosomal membrane (Figure 3). DOPE-conjugated FRET probes (NBD-PE and N-Rh-PE) were formulated into endosome-mimicking nanoparticles. NBD is normally quenched by the rhodamine, but the NBD signal would rise if disruption of the membrane occurred.. In accordance with the in vivo data, 4A3-Cit proved to be the best. As citronellol is a known membrane disrupter, we believe 4A3-Cit’s unique structure promotes better endosomal escape than the other LNPs.[12]

Figure 3.

Figure 3.

A lipid fusion assay shows 4A3-Cit with the highest lipid fusion percent. A) Visual assay representation showing the emission changes based on fusion. B) Percent of lipid fusion of LNPs with the model endosomal membrane.

To further examine cellular uptake and intracellular trafficking, we performed in vitro experiments using Cy5-labeled mRNA LNPs. The results showed that 4A3-SC8, 4A3-Far, and 4A3-Cit LNPs are all effectively internalized at 4 hours and 24 hours (Figure S10 A and B). There were differences at 4 hours, with the two unsaturated lipids (4A3-Far and 4A3-Cit) LNPs internalizing slightly faster than the saturated (4A3-SC8) LNPs. We further tracked the progression of Cy5 mRNA from the cell membrane to endosomes to lysosomes and quantified co-localization of Cy5 mRNA with lysosomes. Interestingly, there was significantly higher colocalization between 4A3-Far and lysosomes compared to 4A3-SC8 and 4A3-Cit. These results suggest that 4A3-Far LNPs lead to mRNA accumulation in lysosomes and unproductive delivery. Moreover, the reduced colocalization with lysosomes for 4A3-SC8 and 4A3-Cit LNPs helps to explain why they are efficacious. The overall results connect chemical structure to factors including cellular uptake, endosomal escape, and intracellular trafficking.

Building on the discovery of unsaturated 4A3-Cit and understanding of increased lipid fusion, we sought to explore how 4A3-Cit could be used to enhance mRNA delivery in vivo to the liver. We recently reported a technology called Selective Organ Targeting Nanoparticles (SORT) for selective mRNA delivery to different tissues.[13] In one application, mixing two ionizable lipids into a 5-component LNP increased delivery efficacy to the liver. [13a, 14] We hypothesized that 4A3-SC8 and 4A3-Cit could be combined into a SORT LNP to engineer improved lipid formulations for the liver. We previously showed that mRNA delivery efficacy and tissue tropism correlated with the chemical identity and percent incorporation of the added SORT molecule while keeping the molar amount of other molecules constant. We hypothesized increasing the occupied percentage of our unsaturated lipid would promote endosomal escape and improve mRNA delivery. Thus, the following primary formulations were devised: 4A3-SC8 with additional parent lipid, 4A3-Cit with additional parent lipid, and a mixture of the two lipids where one would serve as the parent lipid and the other served as additional supplemental SORT lipid (Figure S2).

First, we aimed to optimize the SORT lipid required to improve mRNA transfection by evaluating formulations across a range of SORT lipid amounts. Additional 4A3-SC8 yielded only mild improvements (Figure S3), but formulations involving additional Cit achieved significant improvements (Figure 4). Once we identified the ideal percentages for the SORT lipids (+5% SC8 and +20/30% of Cit), we tested the cross-over mixtures. Cit+SC8 (5%) performed only slightly better than its parent formulation (Figure S3), but SC8+Cit (20%) surpassed all others with an 18-fold increase of the average luminescence. SC8+Cit (20%) was also superior to its saturated parent lipid and established benchmarks including 5A2-SC8 LNPs and DLin-MC3-DMA LNPs (Figure S9). Interestingly, 8+Cit (30%) performed worse than its Cit (+30%) counterpart, and the reverse was observed with its 20% variant. The data revealed that improvement is accessible by increasing occupancy of the 4A3-Cit, but there is a threshold for the additive effect of Cit. The comparison of the average luminescence suggests that there needs to be a careful balance of ionizable lipids for LNPs to achieve successful increased transfection.

Figure 4.

Figure 4.

4A3-SC8 + Cit (20%) improved Luc mRNA expression in liver 18-fold over the saturated base LNP formulation (4A3-Cit). A) Optimization of Cit SORT lipid. B) Evaluation of cross-over mix using the identified lipids percentages. C) Quantified average luminescence of the liver after 6 hours. D) Molar ratio and percentage of the 5-component SORT LNP formulations. D) Visual representation of formulation. E) Table of details for the base LNP and SORT LNP formulations (Total lipids/mRNA ratio = 40; wt/wt).

In summary, we synthesized unsaturated thiols that enabled access to a library of 91 ionizable lipids. In vitro mRNA delivery screening results revealed differences and SAR that correlated with the location/configuration of the unsaturated bond(s) rather than the simple presence of unsaturation. Selecting the 4A3 amine core to study in vivo, 4A3-Cit demonstrated the highest efficacy. Mechanistic studies using model endosomal membranes indicated that 4A3-Cit demonstrated the highest lipid fusion ability, suggesting its unique tail structure may enhance endosomal escape. 4A3-Cit further established its exceptional utility for mRNA delivery through application in SORT LNPs. SC8+Cit (20%) SORT LNPs improved mRNA delivery 18-fold over parent formulations. The findings from this work aid a deeper understanding of how unsaturation may promote mRNA delivery by increasing endosomal fusion, identify 4A3-Cit as a potent new lipid, and further expand the utility of SORT LNPs for efficacious mRNA delivery.

Supplementary Material

SUP

Acknowledgements.

D.J.S. acknowledges financial support from the National Institutes of Health (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB) (R01 EB025192-01A1), the Cystic Fibrosis Foundation (CFF) (SIEGWA18XX0), the Cancer Prevention and Research Institute of Texas (CPRIT) (RP190251), the American Cancer Society (ACS) (RSG-17-012-01), and the Welch Foundation (I-1855). We acknowledge the UTSW Small Animal Imaging Shared Resource (NIH NCI P30CA142543). S.M.L. acknowledges support from NIH (T32GM127216).

Footnotes

Supporting information for this article is given via a link at the end of the document.

Institute and/or researcher Twitter usernames: @DJSiegwart

References

  • [1].a) Hajj KA, Whitehead KA, Nat. Rev. Mater 2017, 2, 17056; [Google Scholar]; b) Pardi N, Hogan MJ, Porter FW, Weissman D, Nat. Rev. Drug Discovery 2018, 17, 261–279; [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Kowalski PS, Rudra A, Miao L, Anderson DG, Mol. Ther 2019, 27, 710–728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [2].a) Sahin U, Kariko K, Tureci O, Nat. Rev. Drug Discovery 2014, 13, 759–780; [DOI] [PubMed] [Google Scholar]; b) Wei T, Cheng Q, Farbiak L, Anderson DG, Langer R, Siegwart DJ, ACS Nano 2020, 14, 9243–9262; [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Lyu Y, Cui D, Sun H, Miao Y, Duan H, Pu K, Angew. Chem. Int. Ed 2017, 56, 9155–9159; [DOI] [PubMed] [Google Scholar]; d) Lyu Y, He S, Li J, Jiang Y, Sun H, Miao Y, Pu K, Angew. Chem. Int. Ed 2019, 58, 18197–18201. [DOI] [PubMed] [Google Scholar]
  • [3].Wittrup A, Ai A, Liu X, Hamar P, Trifonova R, Charisse K, Manoharan M, Kirchhausen T, Lieberman J, Nat. Biotechnol 2015, 33, 870–876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [4].a) Whitehead K, Langer R, Anderson D, Nat. Rev. Drug Discovery 2009, 8, 129–138; [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Kanasty R, Dorkin JR, Vegas A, Anderson D, Nat. Mater 2013, 12, 967–977; [DOI] [PubMed] [Google Scholar]; c) Miller JB, Siegwart DJ, Nano Res 2018, 11, 5310–5337; [Google Scholar]; d) Akinc A, Maier MA, Manoharan M, Fitzgerald K, Jayaraman M, Barros S, Ansell S, Du X, Hope MJ, Madden TD, Mui BL, Semple SC, Tam YK, Ciufolini M, Witzigmann D, Kulkarni JA, van der Meel R, Cullis PR, Nat. Nanotechnol 2019, 14, 1084–1087. [DOI] [PubMed] [Google Scholar]
  • [5].a) Kauffman KJ, Webber MJ, Anderson DG, J. Controlled Release 2016, 240, 227–234; [DOI] [PubMed] [Google Scholar]; b) Li J, He Y, Wang W, Wu C, Hong C, Hammond PT, Angew. Chem. Int. Ed 2017, 56, 13709–13712; [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Ramishetti S, Hazan-Halevy I, Palakuri R, Chatterjee S, Naidu Gonna S, Dammes N, Freilich I, Kolik Shmuel L, Danino D, Peer D, Adv. Mater 2020, 32, e1906128; [DOI] [PubMed] [Google Scholar]; d) Sago CD, Lokugamage MP, Paunovska K, Vanover DA, Monaco CM, Shah NN, Gamboa Castro M, Anderson SE, Rudoltz TG, Lando GN, Munnilal Tiwari P, Kirschman JL, Willett N, Jang YC, Santangelo PJ, Bryksin AV, Dahlman JE, Proc. Natl. Acad. Sci. U.S.A 2018, 115, E9944–E9952; [DOI] [PMC free article] [PubMed] [Google Scholar]; e) Xiong H, Liu S, Wei T, Cheng Q, Siegwart DJ, J. Controlled Release 2020, 325, 198–205; [DOI] [PMC free article] [PubMed] [Google Scholar]; f) Wang Y, Tang J, Yang Y, Song H, Fu J, Gu Z, Yu C, Angew. Chem. Int. Ed 2020, 59, 2695–2699; [DOI] [PubMed] [Google Scholar]; g) Zhao X, Chen J, Qiu M, Li Y, Glass Z, Xu Q, Angew. Chem. Int. Ed 2020. [DOI] [PubMed] [Google Scholar]
  • [6].Miller JB, Zhang S, Kos P, Xiong H, Zhou K, Perelman SS, Zhu H, Siegwart DJ, Angew. Chem. Int. Ed 2017, 56, 1059–1063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [7].a) Kauffman KJ, Dorkin JR, Yang JH, Heartlein MW, DeRosa F, Mir FF, Fenton OS, Anderson DG, Nano Lett 2015, 15, 7300–7306; [DOI] [PubMed] [Google Scholar]; b) Li B, Luo X, Deng B, Wang J, McComb DW, Shi Y, Gaensler KM, Tan X, Dunn AL, Kerlin BA, Dong Y, Nano Lett 2015, 15, 8099–8107; [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Cheng Q, Wei T, Jia Y, Farbiak L, Zhou K, Zhang S, Wei Y, Zhu H, Siegwart DJ, Adv. Mater 2018, 30, e1805308. [DOI] [PubMed] [Google Scholar]
  • [8].a) Fenton OS, Kauffman KJ, McClellan RL, Kaczmarek JC, Zeng MD, Andresen JL, Rhym LH, Heartlein MW, DeRosa F, Anderson DG, Angew. Chem. Int. Ed 2018, 130, 13770–13774; [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Zhang XF, Zhao WY, Nguyen GN, Zhang CX, Zeng CX, Yan JY, Du S, Hou XC, Li WQ, Jiang J, Deng BB, McComb DW, Dorkin R, Shah A, Barrera L, Gregoire F, Singh M, Chen DL, Sabatino DE, Dong YZ, Science Adv 2020, 6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [9].Quinn PJ, Joo F, Vigh L, Prog. Biophys. Mol. Bio 1989, 53, 71–103. [DOI] [PubMed] [Google Scholar]
  • [10].Zhou K, Nguyen LH, Miller JB, Yan Y, Kos P, Xiong H, Li L, Hao J, Minnig JT, Zhu H, Siegwart DJ, Proc. Natl. Acad. Sci. U.S.A 2016, 113, 520–525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [11].Jayaraman M, Ansell SM, Mui BL, Tam YK, Chen JX, Du XY, Butler D, Eltepu L, Matsuda S, Narayanannair JK, Rajeev KG, Hafez IM, Akinc A, Maier MA, Tracy MA, Cullis PR, Madden TD, Manoharan M, Hope MJ, Angew. Chem. Int. Ed 2012, 51, 8529–8533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [12].Kopecna M, Machacek M, Novackova A, Paraskevopoulos G, Roh J, Vavrova K, Sci. Rep 2019, 9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [13].a) Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ, Nat. Nanotechnol 2020, 15, 313–320; [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Wei T, Cheng Q, Min YL, Olson EN, Siegwart DJ, Nat. Commun 2020, 11, 3232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [14].Miao L, Lin J, Huang Y, Li L, Delcassian D, Ge Y, Shi Y, Anderson DG, Nat. Commun 2020, 11, 2424. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

SUP

RESOURCES